Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» aducanumab
aducanumab
Biogen's Aducanumab: A Look at the Drug’s History and Recent Updates
BioSpace
Sat, 03/27/21 - 12:14 pm
Biogen
Eisai
aducanumab
Alzheimer's disease
Big pharma’s key catalysts in the second quarter
EP Vantage
Wed, 03/24/21 - 10:04 am
Biogen
Alzheimer's disease
aducanumab
Sanofi
breast cancer
FDA
Biogen outlines 10M-patient opportunity for Alzheimer's drug in US
Biopharma Reporter
Tue, 03/16/21 - 10:48 pm
Biogen
Alzheimer's disease
aducanumab
Clarivate Drugs to Watch Report Highlights Four Likely Blockbusters Among Drugs Launching in 2021
PR Newswire
Tue, 03/9/21 - 10:45 am
Clarivate
Biogen
Eisai
aducanumab
UCB Pharma
bimekizumab
Relugolix
Pfizer
Takeda
Myovant
vericiguat
Bayer
Merck
Where Will Biogen Be in 5 Years?
Motley Fool
Tue, 02/23/21 - 10:40 am
Biogen
aducanumab
Alzheimer's disease
A safer Alzheimer's drug than Biogen's aducanumab? Denali-WashU drug shows better profile in mice
Fierce Biotech
Thu, 02/18/21 - 11:04 am
Alzheimer's disease
Denali Therapeutics
Biogen
aducanumab
HAE-4
Biogen laser-focused on Alzheimer's drug as rest of business falters
BioPharma Dive
Wed, 02/3/21 - 10:55 pm
Biogen
earnings
aducanumab
Alzheimer's disease
FDA extends review period for Biogen's Alzheimer's drug
Reuters
Fri, 01/29/21 - 10:06 am
Biogen
Eisai
FDA
aducanumab
Alzheimer's disease
Aducanumab tops 2021’s biggest potential launches
EP Vantage
Mon, 01/18/21 - 01:04 pm
drug launches
Biogen
Eisai
aducanumab
efgartigimod
Argenx
Evrenzo
FibroGen
Astellas
AstraZeneca
Leqvio
Novartis
UCB Pharma
bimekizumab
Ascendis Pharma
Bluebird Bio
Bristol-Myers Squibb
ide-cel
liso-cel
AXS-05
Axsome Therapeutics
voclosporin
Aurinia
Here's the Top FDA Decision to Watch in 2021
Motley Fool
Sun, 01/17/21 - 04:56 pm
FDA
Biogen
aducanumab
Alzheimer's disease
3 FDA Dates Biotech Investors Should Circle in 2021
Motley Fool
Sat, 12/26/20 - 08:27 pm
FDA
biotech
Bluebird Bio
ide-cel
Multiple Myeloma
Biogen
aducanumab
Alzheimer's disease
targeted therapeutics
umbralisib
maringal zone lymphoma
Public Citizen Demands Investigation into "Inappropriate Collaboration" Between FDA and Biogen Over Alzheimer's Drug
BioSpace
Wed, 12/9/20 - 10:59 pm
Biogen
OIG
HHS
aducanumab
Public Citizen
Alzheimer's disease
Biogen ‘continues to work’ with FDA on Alzheimer's drug candidate despite regulatory setback
Biopharma Reporter
Tue, 11/10/20 - 10:36 am
Biogen
FDA
Alzheimer's disease
aducanumab
5 takeaways from the FDA's high-stakes meeting for Biogen's Alzheimer's drug
BioPharma Dive
Mon, 11/9/20 - 08:56 pm
Biogen
FDA
Alzheimer's disease
aducanumab
clinical trials
amyloid
Why Biogen Stock Is Tanking Today
Motley Fool
Mon, 11/9/20 - 11:02 am
Biogen
aducanumab
FDA
Alzheimer's disease
FDA advisers vote against Biogen's Alzheimer's drug, leaving its future in doubt
Biopharma Dive
Fri, 11/6/20 - 08:46 pm
Biogen
aducanumab
FDA
advisory panels
Alzheimer's disease
The FDA's insider review on aducanumab was all about politics, not science, and it threatens patients and the biopharma industry alike
Endpoints
Fri, 11/6/20 - 10:19 am
FDA
Biogen
aducanumab
Alzheimer's disease
FDA scientists appear to offer major endorsement of Biogen’s controversial Alzheimer’s treatment
Stat
Wed, 11/4/20 - 10:50 am
Biogen
aducanumab
Alzheimer's disease
FDA
advisory panels
The meeting that could change Alzheimer's treatment
BioSpace
Tue, 11/3/20 - 09:44 pm
Biogen
aducanumab
Alzheimer's disease
FDA
Biogen's reprieve as critic recused from aducanumab panel, but analysts still read rejection in the tea leaves
Fierce Biotech
Tue, 11/3/20 - 10:59 am
Biogen
aducanumab
FDA
advisory panel
Alzheimer's disease
Pages
« first
‹ previous
1
2
3
4
5
6
7
next ›
last »